Vertex Pharmaceuticals

Eli Lilly

Neurocrine Biosciences

Alnylam Pharmaceuticals

Regeneron Pharmaceuticals

Crinetics Pharmaceuticals Inc

Biogen

Medtronic

Ionis Pharma

Stryker

Tema Neuroscience and Mental Health ETF

MNTL is actively managed, concentrating on companies engaged in addressing disorders of the central nervous system and mental health worldwide. Using both top-down and bottom-up stock selection, the fund identifies innovative companies deemed attractive.

Tech investing poses one of the more important, and more fascinating, questions before investors entering 2025. Tech firms contributed outsized returns for the whole market, but do they pose concentration risks?

Hone Your Biotech Allocation in Neuroscience ETF MNTL

Global X Health & Wellness Thematic ETF

Global X China Biotech Innovation ETF

Global X MSCI China Communication Services ETF

Global X China Energy ETF

Global X MSCI China Health Care ETF

Global X China Industrials

Global X MSCI China Information Technology ETF

Global X China Materials ETF

Global X MSCI China Real Estate ETF

Global X MSCI China Consumer Staples ETF

Global X MSCI China Utilities ETF

Global X China Financials ETF

Global X Next Emerging & Frontier ETF

iShares U.S. Fixed Income Balanced Risk Factor ETF

Strategy Shares Gold-Hedged Bond ETF

Global X Funds-Global X Green Building Etf

iShares High Yield Bond Factor ETF

iShares Investment Grade Bond Factor ETF

Global X Carbon Credits Strategy ETF

Global X MSCI Pakistan ETF

Global X MSCI Portugal ETF

Global X Cannabis ETF

Defiance Treasury Alternative Yield Etf

iShares USD Bond Factor ETF

Global X Metaverse ETF

Mohr Industry Nav Etf

Although 14 new ETFs debuted in the U.S. this past week, closure announcements came in even stronger, largely due to Global X pruning its lineup. Launches during the week included funds from BondBloxx, WisdomTree, Innovator, JPMorgan, and Range ETFs.

This Week in ETFs: Closures Outnumber New ETFs

News for Tema Neuroscience and Mental Health ETF ETF (MNTL)